What is Brookline Cap M’s Estimate for CRSP Q1 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Brookline Cap M issued their Q1 2026 earnings per share estimates for CRISPR Therapeutics in a report released on Thursday, February 12th. Brookline Cap M analyst L. Cann anticipates that the company will post earnings per share of ($1.11) for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Brookline Cap M also issued estimates for CRISPR Therapeutics’ Q2 2026 earnings at ($1.22) EPS, Q3 2026 earnings at ($1.36) EPS, Q4 2026 earnings at ($1.30) EPS and FY2030 earnings at $139.88 EPS.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC boosted their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Friday. Wedbush cut their price target on CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 5th. Evercore ISI restated an “outperform” rating and set a $74.00 price objective on shares of CRISPR Therapeutics in a research note on Friday. Chardan Capital set a $76.00 price objective on CRISPR Therapeutics in a report on Saturday. Finally, Robert W. Baird reduced their target price on CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Eleven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $67.35.

CRISPR Therapeutics Trading Up 8.5%

NASDAQ CRSP opened at $53.07 on Monday. The stock has a market cap of $5.09 billion, a P/E ratio of -8.14 and a beta of 1.72. The company’s fifty day simple moving average is $54.22 and its 200-day simple moving average is $57.35. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The company had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. During the same quarter in the prior year, the company earned ($1.01) EPS. The firm’s revenue was down 97.8% compared to the same quarter last year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the transaction, the chief executive officer directly owned 134,201 shares in the company, valued at approximately $8,082,926.23. This trade represents a 30.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CRSP. Koss Olinger Consulting LLC raised its position in CRISPR Therapeutics by 29.8% in the second quarter. Koss Olinger Consulting LLC now owns 42,197 shares of the company’s stock worth $2,052,000 after acquiring an additional 9,685 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of CRISPR Therapeutics by 59.7% in the 2nd quarter. Legal & General Group Plc now owns 129,567 shares of the company’s stock worth $6,302,000 after purchasing an additional 48,412 shares in the last quarter. Intellectus Partners LLC acquired a new stake in CRISPR Therapeutics during the second quarter valued at approximately $284,000. State of New Jersey Common Pension Fund D boosted its holdings in CRISPR Therapeutics by 20.8% during the second quarter. State of New Jersey Common Pension Fund D now owns 50,185 shares of the company’s stock worth $2,441,000 after buying an additional 8,645 shares in the last quarter. Finally, Philadelphia Trust Co. acquired a new position in CRISPR Therapeutics in the second quarter worth approximately $2,444,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics News Roundup

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Casgevy commercial momentum—management highlighted that Casgevy generated about $54M in Q4 and $116M for full‑year 2025, supporting the view that adoption for the company’s approved SCD/TDT therapy is expanding and producing meaningful sales. CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
• Positive Sentiment: Analyst upgrade/price‑target lift—Needham raised its price target to $82 and maintained a Buy rating, signaling institutional conviction that shares have upside on continued commercial execution. CRSP Price Target Raised by Needham
• Neutral Sentiment: Official business update and results—CRISPR published its Q4 and full‑year 2025 results and a business update emphasizing pipeline progress and upcoming label expansion plans; this is informative for longer‑term thesis but contains limited near‑term financial guidance. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Positive retail narrative—an upbeat Fool feature framed the company as a “blastoff‑ready” biotech pick for 2026, which can boost retail buying interest but is opinion‑driven. The Blastoff-Ready Biotech Stock You’ll Kick Yourself for Not Buying in 2026
• Neutral Sentiment: Short‑interest data appears anomalous—recent reports show short interest listed as 0 shares (likely a reporting/data issue), so short‑interest signaling is unclear and should be treated cautiously.
• Negative Sentiment: Quarterly miss and wider loss—CRSP reported Q4 EPS of ($1.37) versus consensus ($1.15) and revenue of $0.86M versus $4.72M expected; revenue fell sharply year‑over‑year, underscoring near‑term financial pressure and a negative margin/earnings backdrop. CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.